Prognostic value of epidermal growth factor receptor, p53 and galectin-3 expression in papillary thyroid carcinoma

Journal of International Medical Research

Volumn 41, Issue 3, 2013, Pages 825-834

  Lee, Yu Mi ^a   Lee, Jae Bok ^b  

^a University of Ulsan College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

EGFR; galectin 3; p53; Papillary thyroid carcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GALECTIN 3; PROTEIN P53;

ADULT; ARTICLE; CANCER PROGNOSIS; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SCORING SYSTEM; SEX DIFFERENCE; SUBTOTAL THYROIDECTOMY; THYROID PAPILLARY CARCINOMA; TUMOR INVASION; TUMOR VOLUME;

EGFR; GALECTIN-3; P53; PAPILLARY THYROID CARCINOMA;

ADULT; AGE FACTORS; CARCINOMA; FEMALE; FOLLOW-UP STUDIES; GALECTIN 3; GENE EXPRESSION; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SEX FACTORS; THYROID NEOPLASMS; THYROIDECTOMY; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84887331429     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/0300060513477312     Document Type: Article

References (35)

1. Leenhardt L,Bernier MO,Boin-Pineau MH,et al.Advances in diagnostic practices affect thyroid cancer incidence in France.Eur J Endocrinol. 2004;150:133-139.
2. Sherman SI.Thyroid carcinoma.Lancet. 2003;361:501-511.
3. Lang BH,Lo CY,Chan WF,et al.Prognostic factors in papillary and follicular thyroid carcinoma: their implications for cancer staging.Ann Surg Oncol. 2007;14:730-738.
4. Eustatia-Rutten CF,Corssmit EP,Biermasz NR,et al.Survival and death causes in differentiated thyroid carcinoma.J Clin Endocrinol Metab. 2006;91:313-319.
5. Giusti F,Falchetti A,Franceschelli F,et al.Thyroid cancer: current molecular perspectives.J Oncol. 2010;2010:351679-351679.
6. Chiu CG,Strugnell SS,Griffith OL,et al.Diagnostic utility of galectin-3 in thyroid cancer.Am J Pathol. 2010;176:2067-2081.
7. Fernández PL,Merino MJ,Gómez M,et al.Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue.J Pathol. 1997;181:80-86.
8. Hosal SA,Apel RL,Freeman JL,et al.Immunohistochemical localization of p53 in human thyroid neoplasms: correlation with biological behavior.Endocr Pathol. 1997;8:21-28.
9. Godballe C,Asschenfeldt P,Jørgensen KE,et al.Prognostic factors in papillary and follicular thyroid carcinomas: p53 expression is a significant indicator of prognosis.Laryngoscope. 1998;108:243-249.
10. Hay ID,Thompson GB,Grant CS,et al.Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients.World J Surg. 2002;26:879-885.
11. The revised American Thyroid Association management guidelines 2009 for patients with differentiated thyroid cancer: an evidence-based risk-adapted approach.Clin Oncol (R Coll Radiol). 2010;22:472-474.
12. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Endocrine Organs. DeLellis RALloyd RVHeitz PU, ed. Lyon, France: IARC Press; 2004:.
13. AJCC Cancer Staging Manual. 7th ed. New York: Springer, 2010.Edge SBByrd DRCompton CC, ed. New York: Springer; 2010:.
14. Hay ID,Bergstralh EJ,Goellner JR,et al.Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989.Surgery. 1993;114:1050-1058.
15. Piemonte M.TNM - classification of malignant tumors (VI edition - 2002). Innovations in the classification of head and neck neoplasms.Acta Otorhinolaryngol Ital. 2003;23:132-135.
16. Carcangiu ML,Zampi G,Pupi A,et al.Papillary carcinoma of the thyroid. A clinicopathologic study of 241 cases treated at the University of Florence, Italy.Cancer. 1985;55:805-828.
17. Mazzaferri EL.Papillary thyroid carcinoma: factors influencing prognosis and current therapy.Semin Oncol. 1987;14:315-332.
18. Andersen PE,Kinsella J,Loree TR,et al.Differentiated carcinoma of the thyroid with extrathyroidal extension.Am J Surg. 1995;170:467-470.
19. Passler C,Prager G,Scheuba C,et al.Application of staging systems for differentiated thyroid carcinoma in an endemic goiter region with iodine substitution.Ann Surg. 2003;237:227-234.
20. Lang B,Lo CY,Chan WF,et al.Restaging of differentiated thyroid carcinoma by the sixth edition AJCC/UICC TNM staging system: stage migration and predictability.Ann Surg Oncol. 2007;14:1551-1559.
21. Lang BH,Lo CY,Chan WF,et al.Staging systems for papillary thyroid carcinoma: a review and comparison.Ann Surg. 2007;245:366-378.
22. Rezk S,Khan A.Role of immunohistochemistry in the diagnosis and progression of follicular epithelium-derived thyroid carcinoma.Appl Immunohistochem Mol Morphol. 2005;13:256-264.
23. Yang H,Jiang D,Li W,et al.Defective cleavage of membrane bound TGFalpha leads to enhanced activation of the EGF receptor in malignant cells.Oncogene. 2000;19:1901-1914.
24. Arteaga CL.Epidermal growth factor receptor dependence in human tumors: more than just expression?.Oncologist. 2002;7:31-39.
25. van der Laan BF,Freeman JL,Asa SL.Expression of growth factors and growth factor receptors in normal and tumorous human thyroid tissues.Thyroid. 1995;5:67-73.
26. Duh QY,Siperstein AE,Miller RA,et al.Epidermal growth factor receptors and adenylate cyclase activity in human thyroid tissues.World J Surg. 1990;14:410-418.
27. Mizukami Y,Nonomura A,Hashimoto T,et al.Immunohistochemical demonstration of epidermal growth factor and c-myc oncogene product in normal, benign and malignant thyroid tissues.Histopathology. 1991;18:11-18.
28. Akslen LA,Myking AO,Salvesen H,et al.Prognostic impact of EGF-receptor in papillary thyroid carcinoma.Br J Cancer. 1993;68:808-812.
29. Aasland R,Akslen LA,Varhaug JE,et al.Co-expression of the genes encoding transforming growth factor-α and its receptor in papillary carcinomas of the thyroid.Int J Cancer. 1990;46:382-387.
30. Akslen LA,Varhaug JE.Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival.Cancer. 1995;76:1643-1654.
31. Dobashi Y,Sakamoto A,Sugimura H,et al.Overexpression of p53 as a possible prognostic factor in human thyroid carcinoma.Am J Surg Pathol. 1993;17:375-381.
32. Fagin JA,Matsuo K,Karmakar A,et al.High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.J Clin Invest. 1993;91:179-184.
33. Donghi R,Longoni A,Pilotti S,et al.Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland.J Clin Invest. 1993;91:1753-1760.
34. Machens A,Hauptmann S,Dralle H.Disparities between male and female patients with thyroid cancers: sex difference or gender divide?.Clin Endocrinol (Oxf). 2006;65:500-505.
35. Perillo NL,Marcus ME,Baum LG.Galectins: versatile modulators of cell adhesion, cell proliferation, and cell death.J Mol Med (Berl). 1998;76:402-412.